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Abstract 
The past decade has witnessed numerous publications on mesenchymal stem cells (MSC), which have 
great potential in regenerative medicine. MSC from various types of origins exhibit different 
characteristics, which may relate to the maintenance role of MSC in that specific source. Reports have 
emerged that among the most widely investigated sources, umbilical cord (UC) or umbilical cord blood 
(UCB) derived MSC throw advantages over bone marrow (BM) derived MSC due to their close to fetal 
origin. Here the methodologies used to separate MSC from UC or UCB, and the intrinsic properties, 
including proliferation capacity, multipotency, cytokine profile, cell surface protein expression and 
gene expression, between UC, UCB and BM derived MSC, are discussed in details, though may not in 
a full picture, for the first time. 
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Introduction 
Thirty years ago, Friedenstein first identified fibroblastoid colony forming units (CFU-F) initiated by 
single cells in mouse bone marrow (BM) [1]. These cells, when they are demonstrated to be 
self-renewing and multipotent (reviewed in [2]), have been widely termed mesenchymal stem cells 
(MSC), although questions have been raised about the accuracy of the terminology [3]. They are 
known to provide the supporting cells for angiogenesis, exhibit a strong immunosuppressive activity 
which can reduce the incidence of graft-versus-host disease (GvHD) following allogeneic haemopoietic 
stem cell (HSC) transplantation [4-6] and may also be used for the treatment of autoimmune diseases 
[7]. Moreover, MSC may be a safer candidate than embryonic stem cells (ESC) for in vivo application, 
as ESC were indicated with karyotypic abnormalities during culture expansion and undergo 
tumorigenesis in vivo which is host-dependent [8, 9] , while MSC are reported with high chromosomal 
stability and lower tendency to form neoplasm in the recipient [10, 11]. Previous opposite findings 
about the malignant transformation of MSC were later withdrawn as they were caused by cross 
contamination of immortal cell lines [12, 13]. Even though MSC turn out to be attractive candidates for 
regenerative medicine [14-17], and have been universally explored both in vitro and in vivo in recent 
years, their nature is yet fully understood. 
Bone marrow was the site where MSC were first harvested and the most widely recognized source of 
MSC, though recent researches have identified several alternative sources with cell characteristics 
similar to MSC, including adipose tissue (AT) [18, 19], skeletal muscle, dermis (reviewed in [20]), 
human placenta [21-23], trabecular bone [24], lung [25], umbilical cord (UC) and umbilical cord blood 
(UCB)[26-34]. It is well recognized that MSC isolated from different origins possess a similar 
spindle-shaped morphology, and share the core marker profile defined by Dominici [35]. Despite the 
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morphological similarities, MSC cultures exhibit considerable degree of variabilities in terms of their 
differentiation potentials and gene expressions, which may in part correlate with cell surface phenotype 
and with the heterogeneous nature of the cultured cells [2, 36, 37], and these differences should be 
carefully considered while utilizing MSC for regenerative tissue repair. Umbilical cord and Umbilical 
cord blood, as extraembryonic tissues that form the link between mother and fetus, represent unique 
advantages over adult sources, which in conjunction with their abundant availabilities and non-invasive 
acquisition methodology have attracted a great amount of attention in recent years. In this paper, the 
phenotype at gene and protein level, and functional variabilities between different sources of MSC 
were discussed, with a focus on the comparison between BM-MSC, UC-MSC and UCB-MSC. 
 
Current status of isolation of MSC from UCB and UC 
Despite that bone marrow represents the main acknowledged source of MSC, the use of BM-MSC is 
not always appreciable in practice due to the high degree of viral infection and the significant decrease 
in yield and proliferative capacity with age [38, 39]. Thus, the search for possible alternative MSC 
sources continues.  
The attempt searching for MSC-like cells from human UCB can be traced back to the beginning of this 
century [30, 40-43]. Other species reported includes equine [44] and ovine [45]. Lee reported 
successful isolation of MSC from cryopreserved UCB, while Kogler found the efficiency of successful 
MSC generation from cryopreserved products was scare [46, 47]. It was described that MSC isolated 
from UCB exhibited two different morphologic phenotypes [43], including flattened fibroblastic cells 
(majority) and spindle-shaped fibroblastic cells (minority). The spindle-shaped clones might represent 
superior sources of MSC as it positively expressed CD90 and possessed a greater tendency in 
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adipogenesis compared to the flattened clones. The success rate of isolating MSC, however, was much 
lower (7~75%) from UCB [18, 44, 48, 49], while it was 100% from BM, AT and UC [50]. The low 
success rate of isolation UCB MSC may due to the very low frequency of circulating MSC in cord 
blood, which was 0.002 ±0.004 per 10
6
 initially plated cells whilst the number of CFU-F from BM was 
83± 61/10
6
 [18].  
The UC contains two arteries and one vein, surrounded by Wharton’s jelly (WJ), the connective tissue 
rich in proteoglycans and hyaluronic acid. Isolation of MSC from umbilical cord has been documented 
from human [51-55], porcine [56], equine [57] and rat [58]. MSC was identified in UC from several 
distinct compartments, including WJ [23, 33, 59] and perivascular regions (PV) of both the vein [32] 
and arteries [60]. Our previous study showed a similar phenotype and multipotency of the MSC from 
different components of UC, except that MSC from PV were more positive for CD146 expression than 
those from WJ [61]. Similar to UCB-derived MSC culture, MSC from UC were also revealed to 
contain two subpopulations [62]: a subpopulation with an average diameter of about 11 μm and a larger 
sized subpopulation of about 19 μm average diameter. The small-sized subpopulation expressed higher 
level of CD73 and CD90, and exhibited higher proliferative capacity.  
 
Methodologies of MSC isolation 
The isolation of MSC from UCB is relatively simple. A similar protocol as processing bone marrow 
with Ficoll-Paque density gradient can be adopted. Briefly, the UCB should be collected into a sterile 
bag containing anti-coagulant, which can be citrate phosphate dextrose [41, 43] or ACD-A buffer [63]. 
Then it should be diluted with at least an equal amount of PBS or HBSS and separated by density 
gradient centrifugation on Ficoll Paque. The mononuclear cells should remain in the buffy coat in the 
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inter phase, which should be collected and washed at least twice before seeded in expansion medium. 
Crucial parameters of successful isolation include a handling time from collection to isolation of less 
than 15 hours, a net volume of more than 33 ml, and a MNC count of more than 1 x 10(8) mononuclear 
cells [41]. The typical density gradient employed was 1.077 g/mL, while recently 1.073 g/mL density 
gradient was found to have a superior effect in that it more efficiently depleted the CD45(+) fraction 
and enriched CFU-F to 1.5 fold and the final MSC yield was increased to 1.8 fold after four passages 
[64]. Besides commonly employed techniques, an osmotic selection method was described with 
hypotonic conditions (>30min) for isolation of MSC based on their unusual resistance to osmotic lysis, 
which can enrich CFU-F from UCB for up to 50-fold compared to classic method [31].  
Processing UC is quite a different story. A summary of the methodologies of UC-MSC isolation 
described above was given in Table 1. As UC contains several MSC harboring compartments, various 
isolation methods have been described. Initially, MSC were harvested from the venous wall of the 
umbilical cord vein using a protocol well established for isolating human umbilical vein endothelial 
cells (HUVEC) [53]. Though culture conditions favored the outgrowth of MSC, the digestion of 
HUVEC at the same time predicts the contamination of HUVEC in the initial culture, and the success 
rate of separating MSC is relatively low (3 out of 50 samples) [54]. Another method was to mince the 
whole UC into 1~2 mm fragments and digest in collagenase type II for 30 min and then trypsinize for 
30 min [52]. This delivers the advantages of convenience, fast and easy operation, however the cell 
population generated by this method might contain both endothelial and epithelial cells. A better 
isolation method was developed in which the mesenchymal tissue was scraped off the WJ after removal 
of blood vessels, followed by digestion in collagenase for 16 hrs and trypsinization for 30min [33]. 
Very recently, a two-step protocol was developed by Fong et al [50, 65] which is more complicated and 
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may help to improve the purity of initial population. This included first cutting the cord into small 
pieces, exposing the inner Wharton’s jelly surface to enzymatic solution for 45 min, then separating the 
Wharton’s jelly and homogenizing with a needle. The initial cell population exhibited two types of 
morphology: epithelioid and short fibroblastic, while only fibroblastic cells remained when passaged. 
While collagenase is the most useful enzyme to release MSC from the UC tissue, it is also possible to 
harvest MSC without enzymatic digestion. La Rocca directly put longitudinally sectioned cord 
fragments with Wharton’s jelly exposed into culture medium for 15 days to obtain primary MSC 
culture based on the “mesenchymal” migratory capability of cells [59], and the isolated UC-MSC were 
demonstrated to express Oct-1 (octamer-binding transcription factor 1), Oct-4 (octamer-binding 
transcription factor 4) and Nanog, markers of embryonic stem cells.  
The first attempt to separate MSC from perivascular tissue was made by Sarugaser and colleagues, 
which gained wide recognition by research groups around the world. In this protocol, first the vessels 
were isolated with surrounding matrix and the two ends were tied to form a loop, which was digested in 
collagenase for 18-24 hours [32]. In our previous study, the best digestion time was 4 hours, as a 
digestion longer than 4 hours resulted in the loss of integrity of the vessels [61]. It may not be 
necessary to seal the two ends of the blood vessel, as attempt has been made with open-ended vessels 
and no signs of contamination was observed in the isolated cells [28].  
Instead of being processed for cell isolation while fresh, it is also reported that UC can be directly 
cryopreserved in autologous cord plasma after the Wharton’s Jelly was extracted and minced [66]. The 
delaying time between UC collection and processing for cell isolation can be as long as five days with 
enough cell numbers obtained for transplantation, which greatly facilitates large-scale handling [67]. 
Some groups used the supplementation of some growth factors, such as EGF, VEGF, or FGF, for the in 
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vitro expansion of UCB-MSC [68, 69] and also for UC-MSC [36, 52, 67, 70], though supplementation 
of growth factors may not be necessary, as reported for UC-MSC [32, 33, 53, 54] and UCB-MSC [71, 
72] in some other papers.  
 
Differences in Self Renewal Capacity 
The proliferation and CFU-F forming capacities of MSC from various sources have been studied. Up to 
date, it was implicated that AT-MSC [18] demonstrated greater proliferation capacity over BM-MSC. 
This phenomenon could be well explained by another study conducted by Wagner et al [42], where 
several proliferation related markers, such as Ki-67, cell division cycle associated 8 (CDCA8), and 
cyclin B2 (CCNB2), were higher expressed in AT-MSC than in BM-MSC. UC-MSC has too been 
proved to proliferate faster with respect to BM-MSC [52, 55, 73-75]. This may be correlated with a 
higher CFU-F initial concentration in UC nucleated cells (1:1609 +/- 0.18) than in BM nucleated cells 
(1:35700 +/- 0.01) [52]. Within the three subpopulations of UC-MSC, namely umbilical cord arterial 
(UCA)-, venous (UCV)-, and Wharton’s Jelly (UCWJ)- derived MSC, UCV cells exhibited a 
significantly higher frequency of CFU-F than UCWJ and UCA cells did [60]. For UCB-MSC, they 
were in some reports characterized by very low proliferative activity [76], while in some other cases 
the proliferation was not restricted by population doublings [41]. When BM-, AT- and UCB- MSC were 
compared, the CFU-F frequency was highest in AT-MSC, and lowest in UCB-MSC [18]. 
It should be noted that proliferation capacity and CFU-F ability are not always associated. In Kern’s 
study [18], among MSC from BM, AT and UCB, UCB-MSC had the lowest CFU-F frequency, but 
could be cultured for the longest period and showed the highest proliferation capacity.  
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Differences in Multipotency 
Despite the fact that MSC from different sources have been illustrated to possess the ability to 
differentiate down the typical mesodermal lineages, their differentiation patterns differ to some degree. 
The relevant findings are discussed as below to provide some insight into the distinct differentiation 
capacities between different sources of MSC, as summarized in Table 2. 
Adipogenesis:  
Several independent researches indicated that UCB-MSC showed no or a considerably reduced 
sensitivity to undergo adipogenic differentiation [18, 41, 77]. Induction of adipogenesis in UCB-MSC 
is difficult, although under certain situation a UCB-MSC strain could produce fat droplets [44, 78], and 
occasionally with good fortune, could demonstrate higher lipid accumulation compared to BM-MSC 
[72]. Our previous study [61] has demonstrated that during adipogenesis, the lipid droplets tended to be 
small and accumulated in the cytoplasm far from the nucleus of UC-MSC lining the cell border 
resulting in a ‘circle’ staining appearance, while them tended to be big and gather in the centre of 
BM-MSC with the morphology looked like a bunch of grape [61]. This is indeed consistent with other 
group’s work as retrieved from the literature [59].  
Osteogenesis:  
It was reported that compared with BM-MSC, UCB-MSC exhibited better osteogenic capacity. The 
amounts of Alizarin Red S and alkaline phosphotase activity were 6.9-fold and 2.7-fold greater for 
UCB-MSC than that for BM-MSC in osteogenic culture, respectively [77]. It was reported that 
osteogenic differentiation of human UCV-MSC proceeded more rapidly than BM-MSC [75, 79], 
whereas in our study [61], both UCWJ-MSC and UCV-MSC showed a reduced calcium deposition and 
no alkaline phosphotase (ALP) activity, which is consistent with the findings of Suzdal'tseva’s group 
11 
[80]. The gene expression of ALP in UC-MSC was only 8% of that in BM-MSC (unpublished data). 
Although some researches implicated that AT-MSC lacked the ability to differentiate into osteoblasts 
[81], in a rat spine fusion model, both collagen sponge containing BM-MSC and AT-MSC transfected 
with adeno-BMP-2 enhanced new bone formation to a significantly greater extent when compared with 
the effect of collagen sponge containing BMP-2 only, and the level of the enhancement was 
comparable [82]. Among UCV-, UCA- and UCWJ- MSC, when analyzed for osteogenic potential, 
UCWJ cells were the least effective precursors, whereas UCA-derived cells exhibited the best 
osteogenic potential and developed alkaline phosphatase activity with or without an osteogenic 
stimulus.[60]. 
Chondrogenesis:  
In chondrogenesis, equine AT-MSC pellets had consistently less and slower GAG expression than 
BM-MSC pellets, and demonstrated no evidence of collagen II staining, suggesting a reduced 
chondrogenic potential [83]. UCB-MSC also had limited chondrogenic capacity compared to BM-MSC 
[72]. Conversely, UC-MSC has been confirmed to express more collagens and glycosaminoglycans 
than BM-MSC did after 6 weeks differentiation in a polyglycolic acid (PGA) scaffold, however the 
composition of the collagens UC-MSC produced was mainly collagen type I, whereas collagen type II 
staining was more intense in differenatiated BM-MSC, leading to the hypothesis that UC-MSC may be 
a desirable option for fibrocartilage tissue engineering [84].  
Untypical lineage differentiation:  
Until now, only a few papers have described comparative studies on untypical differentiation of UCB- 
or UC-derived MSC as opposed to BM-MSC. UC-MSC may have higher endothelial differentiation 
potential than BM-MSC [74] in that they had higher expression of the endothelial-specific markers 
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(Flk-1, von Willebrand factor, and vascular endothelial (VE)-cadherin) in endothelial differentiation 
[73]. Moreover, in vitro angiogenesis assay implied that UC-MSC formed higher total length, diameter, 
and area of tubules than differentiated BM-derived counterparts. In pancreatic differentiation study [73], 
after treatment with the inductive stimuli, UC-MSC had higher expression of pancreatic-specific 
markers (PDX-1 and C-peptide) than BM-MSC, intimating their stronger pancreatic differentiation 
potential. In neuronal induction, UC-MSC also had a higher percentage of neuron specific 
enolase-positive cells than had BM-MSC [52]. However, UC-MSC or UCB-MSC may not be a good 
source for stem cell therapy in treating myocardial infarction, as, our previous study [61] has illustrated 
that after 5-Azacytidine-treatment for cardiomyocyte differentiation, human UC or UCB MSC lack the 
expression of cardiomyocyte markers (tropomyosin, connexin 43 and Nkx2·5), while a small 
proportion of BM-MSC did (0.07%).  
 
Differences in Cytokine Profile 
Cytokines are small signaling molecules involved in intercellular communication. They serve as 
molecular messengers in order to regulate the body's response to disease and infection [85]. The 
cytokine secretion profile of BM-MSC has been confirmed by microarray analysis [86] to be composed 
of interleukin (IL) -6, IL-8, monocyte chemotactic protein (MCP) -1, Chemokine (C-C motif) ligand 5 
(CCL5), growth regulated oncogene-ɑ (GRO-ɑ), Interferon (IFN) -Ƴ, IL-1ɑ, transforming growth 
factor (TGF) -ß, angiogenin, oncostatin M, macrophage inflammatory protein (MIP)-1ß, IL-2, IL-4, 
IL-10, IL-12, and IL-13. The expression of granulocyte macrophage colony-stimulating factor 
(GM-CSF) is debatable. In Potian’s study [86], GM-CSF was found to be expressed in BM-MSC, but 
in another study [52], neither granulocyte colony-stimulating factor (G-CSF) nor GM-CSF was 
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detected at mRNA level in BM-MSC. Instead, UC-MSC expressed GM-CSF and weakly expressed 
G-CSF [52], while UCB-MSC did not express G-CSF under serum-free conditions [48]. 
Parallel comparative analysis of cytokine expression profile of BM-MSC, UC-MSC and UCB-MSC at 
protein level and mRNA level were retrieved from three publications [65, 66, 87], and statistically 
re-analyzed in Figure 1. Though some data were not consistent among the three papers, it is noticed 
that all confirmed IL-6 and IL-8 were upregulated in UC-MSC. In UCB-MSC, the expression of IL-6 
was lower, and IL-8 was lower or similar, compared to BM-MSC, as agreed by another report [88]. 
IL-12(A) and IL-15 expression was similar [66] or higher [65, 87] in UC-MSC in contrast to BM-MSC. 
IL12(A) is associated with the induction of apoptosis, indicating UC-derived MSC might have better 
anticancer properties. Though UC-MSC were indicated with higher VEGFR2 expression which 
enabled a higher response to endothelial induction [65], in Yoo’s work [87], VEGF protein expression 
was much lower in UC-MSC. This result is also supported by Friedman’s work [66]. However the 
changes in protein expression may differs from the gene expression of VEGF, as a high VEGF mRNA 
expression on UC-MSC was reported in Fong’s [65] and Lu’s [52] work. From another aspect, VEGFR 
and VEGF expression may not be related during endothelial differentiation, as Alamino’s work [89] 
showed that during endothelial differentiation, UC-MSC showed upregulated VEGFR1 but reduced 
VEGF expression. 
 
Differences in Cell Surface Protein Expression 
With view to the commonly used panel of MSC markers, our study [61] highlighted a difference in the 
relative expression of CD146 and CD106 among different sources of MSC. UCB-MSC had higher 
CD146 expression as compared to BM-MSC or UC-MSC. BM-MSC and CB-MSC were weakly 
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positive for CD106, while UCV-MSC and UCWJ-MSC were negative, which were consistent with the 
findings of other groups [52, 61]. Similarly, AT-MSC also showed lower level of CD106 expression 
compared to BMSC [18, 42, 90]. 
For the expression of other cell surface molecules, back to 2003, a primitive comparative analysis on a 
series of surface molecules (including CD3, CD4, CD11c, CD13, CD14, CD15, CD16, CD19, CD29, 
CD31, CD33, CD34, CD38, CD44, CD45, CD49d, CD54, CD56, CD58, CD62P, CD90, CD104, 
CD105, CD106, CD144, CD166, SH3 and Stro-1) expressed on human AT-MSC and BM-MSC by 
flow cytometry, was initiated [91]. Most of the expressions were comparable within the two 
populations of MSC. Differentially, AT-MSC expressed CD49d (alpha-4 integrin), lacked the 
expression of CD106 (VCAM-1), highly expressed CD54 (ICAM-1) and lowly expressed CD34, while 
BM-MSC were CD49d negative, CD106 positive, dimly expressed CD54 and CD34 negative [91]. A 
higher expression of CD49d was also reported by others in AT-MSC [90] [42] and in UCB-MSC [40]. 
All these differences detected were within a range of adhesion molecules with known function in 
homing and mobilization of hematopoietic stem cells. In comparison with BM-MSC, UC-MSC showed 
down regulation of HLA-ABC [52, 66] and high regulation of HLA-G [59]. A summary of the major 
difference in surface protein expression of BMSC, UC-MSC, UCB-MSC and AT-MSC was given in 
Table 3. 
 
Differences in Gene Expression 
The first comparative study performed on gene expression of different sources of MSC was initiated in 
2004. As expected, MSC from different sources shared a large cohort of gene expression, especially 
when compared to other types of cells such as HUVEC [92] or HS68 fibroblasts [42], revealing their 
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close nature in spite of some minor differences.  
When BM-MSC and UC-MSC were put into contrast, a set of 45 gene expressions, most of which 
related to antimicrobial activity and osteogenesis, were at least 10-fold higher expressed in BM-MSC. 
Conversely, 38 transcripts related to matrix remodeling and angiogenesis were abundantly expressed in 
UC-MSC while they were absent or rare in BM-MSC [92]. These sources-related characteristics 
implicated that BM-MSC would be more committed to osteogenesis, whereas UC-MSC would be more 
committed to angiogenesis [81].  
When BM-MSC and UCB-MSC were compared, several genes involved in mesodermal differentiation 
were noticed [42]. Mesoderm-specific transcript homolog (MEST) was highly expressed in BM-MSC, 
whereas CB-MSC showed the highest expressions of BMP antagonist 1 (CKTSF1B1 or gremlin 1) and 
connective tissue growth factor (CTGF). It is also reported that peroxisome proliferation activated 
receptor gamma (PPARG), which correlated with adipogenic differentiation capacities, and hepatocyte 
growth factor (HGF) and stromal-derived factor 1 (SDF1/CXCL12), were upregulated in UCB-MSC 
[72]. Un-induced BM-MSC had higher expression of markers for chondrogenic differentiation 
(aggrecan 1 (AGC1), collagen X (COL10A1), and cartilage oligomeric protein (COMP)), while 
UCB-MSC showed upregulated expression of genes associated with embryonic development and 
organogenesis, including insulin-like growth factor-binding protein 5 (IGFBP5), frizzled-7 (FZD7), 
rhomboid like protein 2 (RHBDL2), fibulin-1 (FBLN1) and secreted frizzled-related protein 1 (SFRP1) 
[72]. 
More recently, meta-analysis of DNA microarray data on UCWJ-MSC, UCB-MSC and BM-MSC 
pooled from different studies [65] revealed that UCWJ-MSC grouped closest to UCB-MSC and this 
was perhaps because of their close origin. UCWJ-MSC expressed a highest range of stem cell markers 
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and lineage markers compared to UCB-MSC and BM-MSC. In contrast to BM-MSC, UCWJ-MSC 
and UCB-MSC expressed higher number of upregulated oncogenes, and UCWJ-MSC also had more 
upregulated tumour suppressor gene expression than UCB-MSC and BM-MSC did. Importantly, 
UC-MSC were found to express some embryonic stem cells markers including Oct-4 [59] and Nanog 
[79]. 
As a conclusion, differences in gene expression of MSC from various sources, overall, can be classified 
into two catalogs. The first catalog consists of genes related to differentiation or proliferation, the other 
is related to the maintenance of the source where MSC were isolated and possibly reflects the function 
of MSC within that origin.  
 
Discussion 
Bone marrow is the first and most frequently practiced location where MSC can be harvested. Isolation 
of MSC from BM is facilitated by standard operation procedure and high success rate. However the 
clinical inconvenience of the invasion procedure and the limited amount of BM available for in vitro 
cell expansion has become a great restriction on its application and leads to numerous searches with 
inspiration to explore for alternative sources, and to date MSC has been identified from a number of 
locations. Despite these encouraging discoveries, the nature of MSC from the alternative source is 
distinctive with respect to their proliferation and differentiation capacities, cytokine profiles, protein 
and gene expression. This may be to some extent due to the lack of a specific MSC marker, but also the 
existence of a hierarchy of differentially MSC commitment may play a role [93]. Furthermore, the age 
of MSC too matters. Although sparse, evidences have been provided that fetal or close to fetal sources 
contained MSC with relatively undifferentiated phenotype with respect to MSC isolated from adult 
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sources, which may be due to their longer telomeres [94]. As reported, among fetal BM-MSC, 
UC-MSC, AT-MSC and adult BM-MSC, only fetal BM-MSC and UC-MSC were positive for the 
embryonic pluripotency markers Oct-4 and Nanog [79]. Furthermore, MSC from UC and UCB, may be 
better tolerated following allogeneic transplantation as they are isolated from perinatal tissues [95]. As 
noncontroversial, inexhaustible sources, and can be harvested noninvasively at low cost, especially 
with their relatively primitive status, UC- and UCB- MSC are both attractive origins and offer high 
potential for future application.  
As discussed in this paper, since the phenotypes of MSC from different origins are versatile, MSC from 
a specific source may be more efficient for a particular therapeutic target and should be taken into 
consideration when choosing MSC source. For example, from the differences in their differentiation 
potentials, UC-MSC might perform better in blood vessel establishment and cartilage repair, while 
BM-MSC and UCB-MSC might contribute better to bone repair. UCB- and AT- MSC shall not be 
considered for chondrogenesis, and UCB-MSC may also not be a good candidate for adipogenesis. 
UC-MSC has better tumor suppressing properties which makes it a better candidate for anticancer 
treatment. 
To date, the majority of clinical trials are performed with BM-MSC, but as more in vitro investigations 
are going on with other types of MSC, UC-MSC and UCB-MSC start to receive attention in clinical 
applications. A search for clinical trials using MSC in the public clinical trial database 
http://clinicaltrials.gov results in 126 records of BM-MSC, 43 records of UC-MSC, and 26 records of 
UCB-MSC. After exclusion of unrelated records included by the keyword search mode, the numbers of 
clinical trials on MSC include 96 studies of BM-MSC, 30 studies of UC-MSC, and 7 studies of 
UCB-MSC, as summarized in Table 4. Many trials may benefit from the anti-fibrotic effect [96] and 
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immune-modulation capacities [7] of MSC, but they also anticipate to validate the regeneration effect 
of MSC as well. The treated organs represent a wide range including eye, heart, liver, kidney, bone, 
cartilage, blood or blood vessel, etc. From the table it can be seen that the focuses of clinical interest of 
BM-MSC are for bone (18%), liver (15%), cartilage (14%) and heart (14%) repair, while currently 
UC-MSC are mainly tested for liver (23%) and neural (20%) disorders, and UCB-MSC are mainly 
tested for cartilage (29%) and lung (29%) diseases. Encouragingly, some of the clinical focus is in line 
with the characteristics of that specific type of MSC. For example, the relatively higher pancreagenesis 
and neurogenesis potential of UC-MSC may support their application in liver and neural disorders. 
Similarly, the application of BM-MSC in heart diseases is backed by their relatively higher 
cardiomyogenesis potential. However some other trials may not be so superior, such as using 
UCB-MSC for cartilage repair. In the future, more in vitro experimental work revealing the 
differences in the intrinsic nature of different types of MSC may serve as a guide for the design of 
clinical trials. 
It is worrying that due to the lack of consensus markers of MSC, in conjunction with the lack of 
standardization of isolation techniques, experimental results can vary not only from one group to 
another, but also vary from one sample to another, even when they were prepared with the same 
protocol. This has been demonstrated in Markov’s study [72], where significant differences in gene 
expressions were present among MSC from UCB-1 and UCB-2. Furthermore, culturing conditions and 
expansion period in culture may have a great influence on the gene profile of MSC, as reported by 
Jeong’s group [96], when analyzing protein expression of two UCB-MSC populations from the same 
culture, one cell population at passage 3-5, the other population at passage 8, it turned out the 
hydrophobic proteomes of the two populations differed from each other. MSC proteome is intrinsically 
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sensitive to its environment and highly related to its functional state, so extreme caution should be 
taken for experimental design, for example, by keeping the cells in a same culture condition and using 
the same passage of cells for analysis purpose, to make the comparison truly comparable. 
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Figure Legends 
 
Figure 1. Reanalysis of cytokine expression at mRNA and protein level in BM-MSC, UC-MSC 
and UCB-MSC. Top: mRNA level by microarray. In the original paper the signal intensity was 
presented in green/red color, and the standard bar ranged from -3.0 (green) to 3.0 (red). We normalized 
the signal of individual gene expression to the standard bar by Image-Pro Plus 5.1 to quantify the level 
of individual gene expression. The result represents the Mean±SEM of 3 batches of BM-MSC, 8 
batches of UC-MSC, and 2 batches of UCB-MSC, respectively.  Bottom: protein level by 
ELISA-based assay. The concentration of cytokines, expressed in the original paper by –, +, ++, +++, 
was quantified as 0, 50, 500, 5000 pg/ml. The result represents the mean of 3 batches of BM-MSC, 
UC-MSC and UCB-MSC, respectively. Notice the consistant changes in the two graphs of the 
expression level of IL-6, IL-8, IL-12 and IL-15 in UC-MSC and UCB-MSC, compared with BM-MSC. 
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Table 1. Methodologies developed for UC-MSC isolation.  
Referenc
es 
storage 
time 
before 
processin
g 
Cord processing Enzymatic digestion 
solution 
Culture medium Seeding 
density 
Outcome 
Part A MSC isolation from Wharton’s Jelly of UC 
[53, 54] 6~12 hr The inner surface of the 
vessel was filled with 
enzymatic solution to collect 
endothelial  and  
subendothelial cells 
0.1%  collagenase  
in  Medium  199 
at 37ºC for 15 
minutes 
DMEM-lowglucose 
(with 20 mM HEPES, 
100 U/ml penicillin, 
100 µg/ml 
streptomycin, 2 mM 
L-glutamine, 1 mM 
sodium pyruvate, and 
10% FBS.） 
103 
cells/cm2 
Initial cultures contained mostly 
endothelial cells, which were 1 
week later outgrown by 
fibroblast-like cells. A 
homogeneous layer of MSC-like 
cells formed by the third week. 
Success rate was low (3 out of 50 
samples). 
[52] N/A The whole UC was minced 
into 1~2 mm fragments and 
put into digestion solution 
digest in 0.075% 
collagenase type II 
for 30 min and then 
0.125% trypsin for 
30 min with gentle 
agitation at 37ºC 
DMEM-low glucose 
(with and 5% FBS, 10 
ng/mL VEGF, 10 
ng/mL EGF，100 U 
penicillin/streptomycin
, and 2mM 
L-glutamine.) 
1×106 
cells/cm2 
The mean yield of nucleated cells 
was 1×106/cm and the yield of 
adherent cells was 8.6×105/cm. 
By 2 weeks, a monolayer of 
homogenous spindle-like cells 
was formed. 
[33] 1~24 hr Connective tissue was 
scraped off the Wharton’s 
Jelly after removal of blood 
vessels  
digest in 2mg/ml 
collagenase for 16 
hrs and 2.5% trypsin 
for 30min at 37ºC 
with agitation 
DMEM (with 10% 
FBS and 4.5 g/L 
glucose.) 
  
[36, 
52][70] 
2~6 hr First the cord was cut into 
1.5cm pieces, the inner WJ 
surface was exposed to 
enzymatic solution for 45 
min. Then the WJ was 
separated by the blunt 
surface of forceps and passed 
through a 18G needle. 
collagenase type I, 
collagenase type IV 
and 100 IU of 
hyaluronidase in 
DMEM medium at 
37ºC for 45 min 
DMEM-high glucose 
(with 20% FBS, 16 
ng/ml bovine FGF; 1 
mM/L-glutamine, 
1:200 dilution of ITS 
and 
antimycotic-antibiotic 
solution.) 
4.7x106 live 
cells/cm2 
Success rate was 100% (13 out of 
13 samples). Primary culture 
showed epitheliod-like 
morphology. Third passage 
cultures showed fibroblastic-like 
morphology. 
[59] <6 hr The cord was cut into 1.5cm 
pieces, sectioned 
longitudinally to expose the 
WJ, and placed in culture 
medium. After 15 days, cells 
attached to culture surface. 
No digestion. DMEM low-glucose 
(with 10% FCS, 
1xNEAA, 1x 
antibiotics–antimycoti
cs, 2mM L-glutamine.) 
one cord 
piece per 
well in 
6-well 
plates 
In first passage, the cells assumed 
a polymorphic, fibroblast-like 
morphology. 
Part B MSC isolation from perivascular region of UC 
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[32] N/A The vessels of 4~5cm length 
were isolated with 
surrounding matrix, and the 
two ends were tied with 
surgical suture to form a 
loop. After digestion, the 
suspended cells were CD45 
depleted. 
1 mg/ml collagenase 
in PBS at 37°C for 
18-24 hours  
75% α-MEM, 15% 
FBS, and 10% 
antibiotics 
N/A Average yield was 2~5×106 cells 
per cord, representing a 
harvesting yield of 2.5~25×104 
cells/cm of cord and a success 
rate of 100% (n=72). The 
harvested cells exhibited a 
morphologically homogeneous 
“fibroblast-like” appearance.  
[28]  The vessels of 1cm length 
were subjected to enzymatic 
solution.  
an enzyme cocktail 
for 3 h at 37°C. 
  The cells could be isolated in 
sufficient quantities and 
demonstrated a fibroblast-like 
phenotype. 
[66] <24 hr Cord pieces of 0.5~1cm were 
removed of vessels and 
minced, then cryopreserved 
in 10% DMSO and 
heat-inactivated autologous 
cord plasma 
No digestion. RPMI-1640 (with 20% 
FBS, penicillin 100 
mg/ml, streptomycin 
10mg/ml, amphote 
ricin B 250mg/ml, and 
ciproﬂoxacin 10 
mg/ml) 
N/A The viability of thawed UC-MSC 
was consistently > 90%. There 
was also no difference as to 
whether cells were initially 
cryopreserved in either VueLife 
bags or cyrovials. The mean 
doubling time was 2.26 days. 
[67] 1~5 days Cord pieces of 3~5cm pre- 
rinsed in 75% ethanol for 
30s, removed of vessels, 
minced into 0.5 – 1mm 2 
pieces,  
No digestion. DMEM-low glucose 
(with 10% FBS, 2 mM 
L-glutamine, 100 U/ml 
penicillin,  100μg/ml 
streptomycin, 25μg/ml 
Fungizone, 5ng/ml 
basic FGF and 5ng/ml 
EGF.) 
1 cord per 
100×20 
mm petri 
dish 
Cell yield was 1.1~5.0×106 
cells/cord at 21~30d after 
processing. Cells can be derived 4 
and 5 days following the sample 
collection, but the cell yield 
decreased. 
1d: 2.50 ± 0.20 × 106; 2d: 1.30 ± 
0.18 × 106;3d:1.20 ± 0.14 × 106; 
4d: 0.84 ± 0 .07 × 106; 5d: 0.74 ± 
0.10 ×106 
FBS: fetal bovine serum. FCS: fetal calf serum. VEGF: vascular endothelial growth factor. EGF: 
epidermal growth factor. FGF: fibroblast growth factor. ITS: insulin-transferrin-selenium. NEAA: 
non-essential aminoacids. PBS: with phosphate buffered saline. N/A: not available. 
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Table 2. Comparison of multipotency of BM-MSC, UC-MSC, UCB-MSC and AT-MSC. 
 BM-MSC UC-MSC UCB-MSC AT-MSC 
Adipogenesis ++ + [61] -~+ [18, 41, 77]  
Chondrogenesis ++ +++ [84] + [72] + [72] 
Osteogenesis ++ 
+++ [75, 79] or + 
[61] [80] 
+++ [77] - [81] or ++ [82] 
Endothelial 
differentiation 
++ +++ [74]   
Pancreagenesis ++ +++ [73]   
Neurogenesis ++ +++ [52]   
Cardiamyogenesis ++ - [61] - [61]  
Enhanced, reduced: represents enhanced or reduced differentiation potential compared with BM-MSC. 
-: differentiation not detected, ++: differentiation potential of BM-MSC, +++: higher differentiation 
potential than BM-MSC, +: differentiation detected but lower than BM-MSC. 
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Table 3. Surface protein expression of BM-MSC, UC-MSC, UCB-MSC and AT-MSC. 
Proteins References BM-MSC UC-MSC UCB-MSC AT-MSC 
CD106 [61] + - +  
 [52] +++ + -  
 [42] ++~+++    - 
 [90] +~++   - 
 [18] +++  +++ ++ 
CD49d [91] -   + 
 [90] -   -/+ 
 [40]   +  
 [42]    +++ 
 [97]  -/+   
CD54 [91] +   +++ 
CD34 [61] - - -  
 [91] -   -/+~+ 
 [42] - - -  
HLA-ABC [52] ++++ +++   
 [42] ++++  ++ ++ 
 [18] ++++  ++++ ++++ 
 [66] ++ +   
HLA-G [59]  +   
CD146 [61] ++ ++ ++++  
 [98]    + 
The comparison of protein expression in each reference was performed with the same antibody and 
staining protocol. -~++++ represent the percentage of positive subsets in the given MSC population. -: 
0~1%, -/+: 1~5%, +: 5~25%, ++: 25~50%, +++: 50~75%, ++++:>75%. 
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Table 4. Summary of clinical trials using BM-MSC, UC-MSC and UCB-MSC. 
Disease 
classification 
BM-MSC UC-MSC UCB-MSC 
No.of 
trials 
Percentage 
No.of 
trials 
Percentage 
No.of 
trials 
Percentage 
Eye 2 2% 
 
0% 
 
0% 
liver 14 15% 7 23% 
 
0% 
kidney 1 1% 1 3% 
 
0% 
lung 1 1% 1 3% 2 29% 
bone 17 18% 1 3% 0 0% 
cartilage 13 14% 2 7% 2 29% 
muscle 
 
0% 1 3% 
 
0% 
skin 2 2% 1 3% 
 
0% 
blood vessel 5 5% 
 
0% 
 
0% 
Heart disease 13 14% 1 3% 
 
0% 
Gastrointestinal 
disease 
2 2% 1 3% 
 
0% 
Diabetes 6 6% 4 13% 
 
0% 
HSC/blood cell 
support  
0% 1 3% 1 14% 
Limb ischemia 3 3% 
 
0% 
 
0% 
neural disorder 7 7% 6 20% 1 14% 
blood disorders 3 3% 2 7% 
 
0% 
graft rejection 7 7% 1 3% 1 14% 
Total 96 
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